Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

In this episode of Liver Lineup: Updates and Unfiltered Insights, Nancy Reau, MD, and Kimberly Brown, MD, turn their attention to metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), conditions that now dominate hepatology clinics but continue to pose major diagnostic and therapeutic challenges. As new drugs enter the clinic and others advance through the pipeline, the hosts explore what meaningful progress looks like in a disease space defined by heterogeneity, comorbidities, and ongoing uncertainty around long-term outcomes.Key episode timestamps:0:00:00 – Intro + global MASLD burden and mortality; who progresses to severe liver disease.0:03:00 – Very low disease awareness; advanced MASLD often missed.0:06:32 – Weak FIB‑4–based referral patterns; need automated pathways.0:10:54 – Alcohol underreporting; role of PEth in honest discussions.0:15:18 – “Modest” alcohol still harmful in MASLD; no truly safe level.0:19:40 – Semaglutide/GLP‑1 benefits on liver outcomes beyond weight loss.0:23:22 – FGF‑21 agents improving portal hypertension in advanced disease.0:24:03 – Carvedilol less effective for variceal bleed prevention in MASLD.0:28:45 – Closing remarks; call for better disease control and systems of care.